BIOCON - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.6
| Stock Code | BIOCON | Market Cap | 69,424 Cr. | Current Price | 428 ₹ | High / Low | 437 ₹ |
| Stock P/E | 291 | Book Value | 167 ₹ | Dividend Yield | 0.12 % | ROCE | 1.92 % |
| ROE | 1.24 % | Face Value | 5.00 ₹ | DMA 50 | 386 ₹ | DMA 200 | 374 ₹ |
| Chg in FII Hold | 0.13 % | Chg in DII Hold | 2.34 % | PAT Qtr | 67.3 Cr. | PAT Prev Qtr | 111 Cr. |
| RSI | 75.8 | MACD | 18.3 | Volume | 39,70,400 | Avg Vol 1Wk | 39,32,118 |
| Low price | 328 ₹ | High price | 437 ₹ | PEG Ratio | 1.70 | Debt to equity | 0.04 |
| 52w Index | 92.3 % | Qtr Profit Var | 218 % | EPS | 0.23 ₹ | Industry PE | 30.5 |
📊 Financial Overview: Biocon Ltd (BIOCON) has a market cap of ₹69,424 Cr. Quarterly PAT fell to ₹67.3 Cr from ₹111 Cr, reflecting earnings pressure. Debt-to-equity ratio is low at 0.04, indicating minimal leverage. ROCE at 1.92% and ROE at 1.24% highlight weak efficiency. Cash flows remain supported by its biopharma and research operations, but profitability is under strain.
💹 Valuation Indicators: Current P/E of 291 is far above the industry average of 30.5, suggesting extreme overvaluation. P/B ratio is ~2.6 (428 ÷ 167), which is moderate. PEG ratio of 1.70 indicates moderately expensive growth. Intrinsic value appears lower than current price, making the stock richly valued despite sector potential.
🏭 Business Model & Advantage: Biocon operates in biopharmaceuticals, biosimilars, and contract research. Its competitive advantage lies in R&D capabilities, global partnerships, and leadership in biosimilars. However, regulatory challenges, pricing pressures, and weak return ratios limit near-term performance.
📈 Entry Zone: A favorable entry zone would be around ₹350–380, closer to its 200 DMA (₹374) and recent low of ₹328. Current price of ₹428 is at the upper range, making accumulation better on dips.
⏳ Long-Term Holding Guidance: Biocon is strategically important in the biopharma sector with strong R&D and global reach. Long-term investors may hold for exposure to biosimilars and healthcare growth, but fresh entry should be cautious given stretched valuations and weak profitability.
Positive
- 🌟 Strong presence in biopharma and biosimilars.
- 🌟 Low debt-to-equity ratio (0.04).
- 🌟 DII holdings increased by 2.34%.
Limitation
- ⚠️ Extremely high P/E (291) compared to industry average (30.5).
- ⚠️ Weak ROCE (1.92%) and ROE (1.24%).
- ⚠️ Quarterly PAT decline from ₹111 Cr to ₹67.3 Cr.
Company Negative News
- 📉 Earnings decline in the latest quarter.
- 📉 Efficiency ratios remain weak despite sector growth.
Company Positive News
- 📈 DII holdings increased by 2.34%.
- 📈 FII holdings increased slightly by 0.13%.
- 📈 Strong R&D pipeline and global biosimilar partnerships.
Industry
- 🏭 Biopharma industry is expanding globally with demand for biosimilars.
- 🏭 Industry P/E at 30.5 shows moderate valuation compared to Biocon’s premium.
- 🏭 Regulatory hurdles and pricing pressures remain challenges.
Conclusion
✅ Biocon is a biopharma leader with strong R&D and global partnerships. However, valuations are extremely stretched and profitability remains weak. Suitable for long-term holding in a healthcare-focused portfolio, but fresh entry should be considered only near ₹350–380 levels.
For deeper insights, you could explore a peer comparison or a technical chart analysis to complement this fundamental view.